Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Horizant, Regnite

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 812Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Annora’s Generics Gabapentin Receives Tentative Approval in US
    Annora’s Generics Gabapentin Receives Tentative Approval in US

    20 Mar 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220420

    FDA
    20 Mar 2026
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Horizant 22399 (Gabapentin Enacarbil) for Extended-release Tablets 300 mg and 600 mg
    FDA Confirms Paragraph IV Patent Challenge of Horizant 22399 (Gabapentin Enacarbil) for Extended-release Tablets 300 mg and 600 mg

    29 Apr 2019

    //

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-horizant-22399-gabapentin-enacarbil-for-extended-release-tablets-300-mg-and-600-mg-1560927506.pdf

    29 Apr 2019
    Share Share
    Xenoport to seek partner to develop drug; CEO steps down
    Xenoport to seek partner to develop drug; CEO steps down

    01 Oct 2015

    // Rosmi Shaji REUTERS

    http://www.reuters.com/article/2015/10/01/us-xenoport-ceo-idUSKCN0RV5V920151001

    Rosmi Shaji REUTERS
    01 Oct 2015
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.